Oculis acquires lead neuro-ophthalmology candidate Privosegtor from Accure Therapeutics to solidify its emerging leadership in the field
Executive summary: Oculis Holding AG signed an asset purchase agreement with Accure Therapeutics to acquire Privosegtor, a lead clinical candidate in neuro-ophthalmology, on August 10, 2026. The acquisition fortifies Oculis’ pipeline and positions the company as an emerging leader in neuro-ophthalmology, a niche with high unmet medical need and limited competition.
Who is involved: Oculis Holding AG (Nasdaq: OCS / XICE: OCS) and Accure Therapeutics, S.L., with the transaction involving transfer of global rights to Privosegtor.
Likely next: Oculis will advance Privosegtor through clinical development, potentially initiating or expanding trials, while seeking additional partnerships or funding to support progression toward regulatory submission.
On August 10, 2026, Oculis Holding AG announced the execution of an asset purchase agreement with Accure Therapeutics for Privosegtor, its lead clinical-stage asset targeting significant unmet needs in neuro-ophthalmology. The transaction strengthens Oculis’ pipeline and competitive positioning as it advances toward becoming a recognized leader in ophthalmic therapeutics. The deal includes worldwide development and commercialization rights, with no disclosed financial terms in the release. This move aligns with Oculis’ strategy to expand its portfolio through targeted in-licensing and asset acquisitions in high-value ophthalmic indications.
What's next — scenarios
Strategic Synergy Realization (Base Case) (55%)
Oculis successfully integrates Privosegtor into its R&D pipeline, reducing operational friction through focused resource allocation.
- Announcement of new clinical trial protocols for Privosegtor
- Successful completion of asset transfer milestones
Pipeline Acceleration (Upside) (25%)
Oculis captures significant market share in neuro-ophthalmology faster than competitors due to enhanced asset strength.
- Positive interim clinical data readout for Privosegtor
- Partnership announcement with a major pharmaceutical distributor
Integration and Regulatory Friction (Downside) (20%)
The acquisition results in unexpected cash burn or delays in clinical development timelines.
- Delayed clinical trial commencement
- Regulatory inquiries regarding Privosegtor's safety profile
What to watch
- Oculis quarterly R&D expenditure updates (next 90 days)
- Clinical trial registry updates for Privosegtor status (next 60 days)
- Regulatory filings related to neuro-ophthalmology indications (next 90 days)
Timeline
- — Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company (GlobeNewswire)
Analysis — what this means
Likely next events
- Oculis to provide updated development timeline for Privosegtor by Q4 2026
- Potential initiation of Phase 2b trial for Privosegtor in early 2027
- Oculis to present preclinical or clinical data at ARVO 2027
Sectors affected
- Neuro-ophthalmology therapeutics
- Ophthalmic drug development
- Biopharmaceutical M&A in ophthalmology
Regulatory implications
- Privosegtor will require IND-enabling studies and FDA/EMA engagement for clinical advancement
- Any future marketing application will need to demonstrate efficacy in rare neuro-ophthalmic conditions
Historical parallels
- Similar to EyeBio’s acquisition of lorigerlimab assets in 2021 to build neuro-ophthalmology pipeline
- Alder BioPharmers’ 2015 in-licensing of eptinezumab (later Vyepti) for migraine laid foundation for Lundbeck’s neuro-focused portfolio